Japan's Ministry of Health, Labour and Welfare has approved an additional indication for inebilizumab (Uplizna), administered by intravenous infusion at a 100 mg dose, to treat generalized myasthenia gravis (gMG) in patients who do not respond adequately to corticosteroids or non-steroidal immunosuppressants, Tanabe Pharma announced September 16, 2026.¹ Inebilizumab is now the only treatment approved in Japan for gMG with a mechanism of action that targets CD19-positive B cells, according to the company.¹
Key facts
- Drug: Inebilizumab (Uplizna; 100 mg, intravenous infusion; Tanabe Pharma/Amgen)
- Class: Humanized anti-CD19 monoclonal antibody
- Indication: gMG, inadequate response to prior therapy
- Regulatory status: Japan MHLW approval granted September 16, 2026
- Key trial: MINT (NCT04524273); phase 3, 238 patients
- Key data: 1.9-point MG-ADL improvement vs placebo at week 26 (P<.0001)
- Durability: 2.8-point MG-ADL benefit maintained through week 52 (AChR+ subgroup)
- Dosing: 2 initial infusions, then 1 maintenance dose every 6 months
- Prior Japan approvals: NMOSD (2021), IgG4-related disease (2025)
- Disease burden: ~29,000 MG patients in Japan; prevalence 23.1 per 100,000
What did the MINT trial show?
Approval was based on data from the myasthenia gravis inebilizumab trial (MINT; NCT04524273), a randomized, double-blind, placebo-controlled trial that enrolled 238 adults with gMG, including 190 who were acetyl choline receptor antibody (AChR)-positive and 48 who were muscle-specific kinase (MuSK)-positive.¹,² At week 26, inebilizumab showed a 1.9-point difference in Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared with placebo (-4.2 vs -2.2; P<.0001), the trial's primary endpoint.¹ In an exploratory analysis of the AChR-positive subgroup, benefits continued through week 52, the longest randomized-controlled period for a phase 3 gMG trial, with a 2.8-point MG-ADL difference favoring inebilizumab (-4.7 vs -1.9; 95% confidence interval, -3.9 to -1.7).¹ MINT was the largest phase 3 biologic study to include both AChR-positive and MuSK-positive patients and the first to successfully incorporate a steroid taper into its protocol; by week 26, 87.4% of patients on inebilizumab and 84.6% on placebo had reduced their steroid dose to 5 mg or less per day.¹
How does inebilizumab work, and how does it differ from other gMG therapies?
Inebilizumab is a humanized monoclonal antibody that causes targeted, sustained depletion of CD19-positive B cells, including plasmablasts and some plasma cells, thereby suppressing production of pathogenic IgG autoantibodies; its precise mechanism of therapeutic effect is not fully understood. gMG is thought to be primarily driven by AChR and MuSK autoantibodies produced by these CD19-positive B cell populations.¹ Unlike anti-CD20 B-cell-depleting therapies such as rituximab, which target naive and memory B cells, inebilizumab's CD19 target is expressed throughout B-cell development, including on a subset of plasma cells that anti-CD20 agents do not reach.³ After 2 initial infusions, patients require only 1 maintenance dose of inebilizumab every 6 months.¹